CoChat
Sign Up
Cited by 26

The DOI matches its Crossref record.

The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients

Taberna, Miren, Torres, Montserrat, Alejo, María, Mena, Marisa, Tous, Sara, Marquez, Sandra, Pavón, Miquel A., León, Xavier, García, Jacinto, Guix, Marta, Hijano, Rafael, Bonfill, Teresa, Aguilà, Antón, Lozano, Alicia, Mesía, Ricard, Alemany, Laia, Bravo, Ignacio G.·2018·Frontiers in Oncology
DOI 10.3389/fonc.2018.00589PMC PMC6297752
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2018.00589

Cites

Statistics

Figures

Figure 1 Histopathological examples of OPC with EGFR (A) and pEGFR (B) expression.
Figure 1 Histopathological examples of OPC with EGFR (A) and pEGFR (B) expression.CC BY · PubMed Central
Figure 2 Samples disposition and testing for HPV status and all biomarkers.
Figure 2 Samples disposition and testing for HPV status and all biomarkers.CC BY · PubMed Central
Figure 3 Overall survival and disease free survival of locally-advance OPC patients based on Kaplan-Meier curves stratified by biomarkers. Legend: Data on 5 years Overall Survival (A–C) and 5 years disease free survival (D–F) according to three different biomarkers: HPV16 (A,D), EGFR (B,E), and pEGFR (C,F). (A,D) Show OS and DFS Kaplan-Meier curve for HPV16-related and HPV negative samples. (B,E) Show OS and DFS Kaplan-Meier curve for EGFR-positive and EGFR-negative samples. (C,F) Show OS and DFS Kaplan-Meier curve for pEGFR-positive and pEGFR-negative samples.
Figure 3 Overall survival and disease free survival of locally-advance OPC patients based on Kaplan-Meier curves stratified by biomarkers. Legend: Data on 5 years Overall Survival (A–C) and 5 years disease free survival (D–F) according to three different biomarkers: HPV16 (A,D), EGFR (B,E), and pEGFR (C,F). (A,D) Show OS and DFS Kaplan-Meier curve for HPV16-related and HPV negative samples. (B,E) Show OS and DFS Kaplan-Meier curve for EGFR-positive and EGFR-negative samples. (C,F) Show OS and DFS Kaplan-Meier curve for pEGFR-positive and pEGFR-negative samples.CC BY · PubMed Central
Figure 4 Overall survival and disease free survival of of locally-advance OPC patients stratified by combination of HPV16 status and EGFR or pEGFR. Legend: Data on 5 years Overall Survival (A,B) and 5 years disease free survival (C,D) according to the combination of HPV16 status and EGFR or pEGFR. (A,C) Show OS and DFS Kaplan-Meier curve according to HPV16 status and EGFR expression. (B,D) Show OS and DFS Kaplan-Meier curve according to HPV16 status and pEGFR expression. The H0 assumed that all groups have equal OS and DFS.
Figure 4 Overall survival and disease free survival of of locally-advance OPC patients stratified by combination of HPV16 status and EGFR or pEGFR. Legend: Data on 5 years Overall Survival (A,B) and 5 years disease free survival (C,D) according to the combination of HPV16 status and EGFR or pEGFR. (A,C) Show OS and DFS Kaplan-Meier curve according to HPV16 status and EGFR expression. (B,D) Show OS and DFS Kaplan-Meier curve according to HPV16 status and pEGFR expression. The H0 assumed that all groups have equal OS and DFS.CC BY · PubMed Central
Figure 5 Overall survival of locally-advanced HPV16-related patients stratified by HPV16-E5 alone and in combination with EGFR and pEGFR. Legend: Data on 5 years Overall Survival for HPV16-related patients, stratified by HPV16-E5 (A) the combination of HPV16-E5 and EGFR (B) and the combination of HPV16-E5 and pEGFR (C). The H0 assumed that all groups have equal OS.
Figure 5 Overall survival of locally-advanced HPV16-related patients stratified by HPV16-E5 alone and in combination with EGFR and pEGFR. Legend: Data on 5 years Overall Survival for HPV16-related patients, stratified by HPV16-E5 (A) the combination of HPV16-E5 and EGFR (B) and the combination of HPV16-E5 and pEGFR (C). The H0 assumed that all groups have equal OS.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 39

  1. Ndiaye, 2014, HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis, Lancet Oncol, 15, 1319, 10.1016/S1470-2045(14)70471-1 · DOI
  2. Ang, 2010, Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med., 363, 24, 10.1056/NEJMoa0912217 · DOI
  3. Taberna, 2015, Late toxicity after radical treatment for locally advanced head and neck cancer, Oral Oncol, 51, 795, 10.1016/j.oraloncology.2015.05.002 · DOI
  4. Masterson, 2014, De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma, Eur J Cancer, 50, 2636, 10.1016/j.ejca.2014.07.001 · DOI
  5. Taberna, 2017, Human papillomavirus related oropharyngeal cancer, Ann Oncol, 28, 2386, 10.1093/annonc/mdx304 · DOI
  6. Kalyankrishna, 2006, Epidermal growth factor receptor biology in head and neck cancer, J Clin Oncol., 24, 2666, 10.1200/JCO.2005.04.8306 · DOI
  7. Mirghani, 2014, Guily J, Eur J Cancer, 50, 1100, 10.1016/j.ejca.2013.12.018 · DOI
  8. Lawrence, 2015, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, 517, 576, 10.1038/nature14129 · DOI · Paper page
  9. Aquino, 2012, PEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations, Cancer Biol Ther, 13, 967, 10.4161/cbt.20991 · DOI
  10. Ang, 2002, Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma, Cancer Res., 62, 7350
  11. Monteiro, 2014, Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas, Oral Dis., 20, 178, 10.1111/odi.12087 · DOI
  12. zur, 2002, Papillomaviruses and cancer: from basic studies to clinical application, Nat Rev Cancer, 2, 342, 10.1038/nrc798 · DOI
  13. Um, 2014, Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer, J Clin Virol., 61, 94, 10.1016/j.jcv.2014.06.019 · DOI · Paper page
  14. DiMaio, 2013, The E5 proteins, Virology, 445, 99, 10.1016/j.virol.2013.05.006 · DOI
  15. Leechanachai, 1992, The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus, Oncogene, 7, 19
  16. Straight, 1995, The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes, J Virol., 69, 3185, 10.1128/JVI.69.5.3185-3192.1995 · DOI
  17. Mena, 2018, Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients, Oral Oncol., 78, 137, 10.1016/j.oraloncology.2018.01.010 · DOI
  18. Castellsagué, 2016, HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients, J Natl Cancer Inst, 108, djv403, 10.1093/jnci/djv403 · DOI
  19. Halec, 2013, Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma, Br J Cancer., 109, 172, 10.1038/bjc.2013.296 · DOI
  20. Grønhøj, 2014, Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review, Br J Cancer, 110, 1587, 10.1038/bjc.2014.42 · DOI
  21. Prigge, 2017, Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis, Int J Cancer, 140, 1186, 10.1002/ijc.30516 · DOI
  22. Alemany, 2015, Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide, Int J Cancer, 136, 98, 10.1002/ijc.28963 · DOI
  23. Jordan, 2012, Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials, Am J Surg Pathol, 36, 945, 10.1097/PAS.0b013e318253a2d1 · DOI
  24. Vojtechova, 2016, Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients' prognosis, Int J Cancer, 138, 386, 10.1002/ijc.29712 · DOI
  25. Parfenov, 2014, Characterization of HPV and host genome interactions in primary head and neck cancers, Proc Natl Acad Sci USA., 111, 15544, 10.1073/pnas.1416074111 · DOI
  26. Mesri, 2014, Human viral oncogenesis: a cancer hallmarks analysis, Cell Host Microbe, 15, 266, 10.1016/j.chom.2014.02.011 · DOI
  27. Nicholson, 2001, EGFR and cancer prognosis, Eur J Cancer, 37, 9, 10.1016/S0959-8049(01)00231-3 · DOI
  28. Hayes, 2015, Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors, J Clin Oncol, 33, 3227, 10.1200/JCO.2015.62.1086 · DOI
  29. Keck, 2015, Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes, Clin Cancer Res, 21, 870, 10.1158/1078-0432.CCR-14-2481 · DOI
  30. Kumar, 2008, EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer, J Clin Oncol, 26, 3128, 10.1200/JCO.2007.12.7662 · DOI
  31. Romanitan, 2013, EGFR and phosphorylated EGFR in relation to HPV and clinical outcome in tonsillar cancer, Anticancer Res., 33, 1575
  32. Chung, 2006, Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas, J Clin Oncol, 24, 4170, 10.1200/JCO.2006.07.2587 · DOI
  33. Young, 2011, Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma, Cancer Epidemiol Biomarkers Prev, 20, 1230, 10.1158/1055-9965.EPI-10-1262 · DOI
  34. Bossi, 2016, Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma, Oncotarget, 7, 74362, 10.18632/oncotarget.11413 · DOI
  35. Fakhry, 2014, RTOG Ret 0129/0522 recurrence and HPV status: human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma, J Clin Oncol., 32, 3365, 10.1200/JCO.2014.55.1937 · DOI
  36. Giralt, 2015, Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial, Lancet Oncol, 16, 221, 10.1016/S1470-2045(14)71200-8 · DOI
  37. Ou, 2016, Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: does human papilloma virus play a role?, Oral Oncol, 59, 50, 10.1016/j.oraloncology.2016.05.019 · DOI
  38. Mehanna, 2018, Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial, Lancet, 10.1016/S0140-6736(18)32752-1 · DOI
  39. Gillison, 2018, Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial, Lancet, 10.1016/S0140-6736(18)32779-X · DOI

Cited by

See all 26

Metadata

Authors
Taberna, M., Torres, M., Alejo, M., Mena, M., Tous, S., Marquez, S., Pavón, M. A., León, X., García, J., Guix, M., Hijano, R., Bonfill, T., Aguilà, A., Lozano, A., Mesía, R., Alemany, L., & Bravo, I. G.
Venue
Frontiers in Oncology
Publisher
Frontiers Media SA
Published
2018-12-11
Volume
8
ISSN
2234-943X
DOI
10.3389/fonc.2018.00589
PMC
PMC6297752
Cited by
26
References
0
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients. https://app.cochat.ai/papers/10.3389/fonc.2018.00589
The paper
Taberna, M., Torres, M., Alejo, M., Mena, M., Tous, S., Marquez, S., Pavón, M. A., León, X., García, J., Guix, M., Hijano, R., Bonfill, T., Aguilà, A., Lozano, A., Mesía, R., Alemany, L., & Bravo, I. G. (2018). The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients. Frontiers in Oncology. https://doi.org/10.3389/fonc.2018.00589